Single-cell analyses reveal key immune cell subsets associated with response to PD-L1 blockade in triple-negative breast cancer.
By Yuanyuan Zhang, Hongyan Chen, H. Mo, Xueda Hu, Ranran Gao, Yahui Zhao, Baolin Liu, L. Niu, Xiaoying Sun, Xiao Yu and 10 more. Cancer Cell, 2021
650 citations recorded by the source corpus.
In triple-negative breast cancer (TNBC), the benefit of combining chemotherapy with checkpoint inhibitors is still not very clear. We utilize single-cell RNA- and ATAC-sequencing to examine the immune cell dynamics in 22 patients with advanced TNBC treated with paclitaxel or its combination with the anti-PD-L1 atezolizumab. We demonstrate that high levels of baseline CXCL13+ T cells are linked to the proinflammatory features of macrophages and can predict effective responses to the combination therapy. In responsive patients, lymphoid tissue inducer (LTi) cells, follicular B (Bfoc) cells, CXCL13+ T cells, and conventional type 1 dendritic cells (cDC1) concertedly increase following the combination therapy, but instead decrease after paclitaxel monotherapy. Our data highlight the importance of CXCL13+ T cells in effective responses to anti-PD-L1 therapies and suggest that their reduction by paclitaxel regimen may compromise the clinical outcomes of accompanying atezolizumab for TNBC treatment.
Subfields: Immunology, Oncology
View Paper: https://www.semanticscholar.org/paper/b9c4efae94b73378a619800de30c162f0c823b01
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Oncology
Citations in the corpus
- Spatially informed clustering, integration, and deconvolution of spatial transcriptomics with GraphST (2023, positive): “Such T cells were also observed by Zhang et al. 50 and Bassez et al. 51 in other human breast cancer samples, and both studies demonstrated their reactivation with anti-PD-L1 therapy to harness their cytotoxicity against the tumor cells.”